Skip to content

Bioenergetic Technology

Using Bioenergetic Technology to heal our bodies and minds

Menu

  • Home
  • About us
  • Contact us

Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for Treatment of Myelodysplastic Syndrome

Uncategorized cornerstone, fda, growing, has-granted, the-growing, today-announced

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the U.S.

Visit link:
Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for Treatment of Myelodysplastic Syndrome

Related posts:

  1. Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 for the Treatment of Small Cell …
  2. Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 in Patients With Locally …
  3. Cornerstone Pharmaceuticals to Present CPI-613 Phase I Results at 2013 American Society of Hematology Annual Meeting
  4. Cornerstone Pharmaceuticals' CPI-613 Phase I Hematologic Malignancies Trial Data Published in AACR's Clinical Cancer …
  • ← DNA link to sugar impact risk for heart disease and diabetes
  • Mental Health Research Symposium in New York City on Oct. 25 →

Recent Posts

  • Reata gets FDA orphan drug status for bardoxolone methyl to treat PAH
  • New Subtle Energy Pattern Research Shows Increases in Cell Growth and Viability
  • Cornerstone Pharmaceuticals' CPI-613 Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting …
  • Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613 in Relapsed or Refractory AML Patients to be …
  • Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Hodgkin's or T-Cell Non …
Copyright © 2024 Bioenergetic Technology. All rights reserved.
Theme: Accelerate by ThemeGrill. Powered by WordPress.